Beyaz Önlük Hipertansiyonlu Hastalarda Serum Lipit Değerleri

Amaç: Beyaz önlük hastalarında serum lipitlerini değerlendirilip esansiyel hipertansiyonlu ve normal tansiyonlularla karşılaştırmak. Gereç ve Yöntem: Üç grup hasta seçtik: 40 esansiyel hipertansiyonlu, 40 beyaz önlük hipertansiyonu ve 40 normal tansiyonlu. Kan örnekleri 12 saatlik açlık sonrası sabahleyin periferik venlerden alındı. Plazma total kolesterol, trigliserit, yüksek yoğunluklu lipoprotein (HDL) kolesterol ve glukoz değerleri Behring cihazı kullanılarak kuru kimyasal enzimatik yolla saptandı. Düşük yoğunluklu lipoprotein (LDL) kolesterol Friedewald formülü kullanılarak hesaplandı. Bulgular: Ortalama ofis kan basıncı değerleri hipertansiyonlu ve beyaz önlük hipertansiyonlu hastalarda kontrol grubuna göre anlamlı olarak yüksek bulundu (p0.05). Sonuç: Bizim verilerimize göre beyaz önlük hipertansiyonlu hastalar normal tansiyonlu insanlarla benzer lipit profiline sahiptirler ve bize göre beyaz önlük hipertansiyonu iyi huylu bir durumdur.

Serum Lipids in Patients with White Coat Hypertension

Aim: Serum lipid levels were investigated in white coat hypertension in comparison with essential hypertension and normotension. Material and Methods: We selected three groups of patients, 40 essential hypertensives, 40 white coat hypertensives, and 40 normotensives. Blood samples were taken in the morning from peripheral veins after 12 hours fasting period. Plasma concentrations of total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, and glucose were determined by the enzymatic dry chemistry method using a Behring apparatus. Low-density lipoprotein (LDL) cholesterol values were computed according to the Friedewald formula. Results: Mean office blood pressure values were significantly higher in hypertensive patients and white coat hypertensive patients than those of control subjects (p0.05). Conclusion: Our data demonstrate that white coat hypertensive patients present similar lipid profile to normotensive people, so in our opinion, the white coat hypertension is a benign condition.

PDF

___

Björklund K, Lind L, Vessby B, Andrén B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year follow-up period: A population-based study of elderly men. Circulation 2002;106:63-8.
Hoegholm A, Bang LE, Kristensen KS, Nielsen JW, Holm J. Microalbuminuria in 411 untreated individuals with established hypertension, white coat hypertension, and normotension. Hypertension 1994;24:101-5.
Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata G, et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: Results from the HARVEST study. Hypertension 1998;31:57-63.
Pierdomenico SD, Lapenna D, Guglielmi MD, Antidormi T, Schiavone C, Cuccurullo F, et al. Target organ status and serum lipids in patients with white coat hypertension. Hypertension 1995;26:801-7.
Cavallini MC, Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Is white coat hypertension associated with arterial disease or left ventricular hypertrophy? Hypertension 1995;26:413-9.
Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic independent of obesity. Metabolism 1990;39:167-74.
Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, et al. "White coat" versus "sustained" borderline hypertension in Tecumseh, Michigan. Hypertension 1990;16:617-23.
Khattar RS, Senior R, Lahiri A. Cardiovascular outcome in white-coat versus sustained mild hypertension: A 10- year follow-up study. Circulation 1998;98:1892-7.
Gosse P, Promax H, Durandet P, Clementy J. ,,White coat" hypertension: No harm for the heart. Hypertension 1993;22:766-70.
Pall D, Juhasz M, Lengyel S, Molnar C, Paragh G, Fulesdi B. Assessment of target-organ damage in adolescent white-coat and sustained hypertensives. J Hypertens 2010;28:2139-44.
Ihm SH, Youn HJ, Park CS, Kim HY, Chang K, Seung KB, et al. Target organ status in white-coat hypertensives: Usefulness of serum procollagen type I propeptide in the respect of left ventricular diastolic dysfunction. Circ J 2009;73:100-5.
Gustavsen PH, Hİegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: A 10-year follow-up study. J Hum Hypertens 2003;17:811-7.
Helvaci MR, Kaya H, Seyhanli M, Yalcin A. White coat hypertension in definition of metabolic syndrome. Int Heart J 2008;49:449-57.
Mancia G, Bombelli M, Seravalle G, Grassi G. Diagnosis and management of patients with white-coat and masked hypertension. Nat Rev Cardiol 2011;8:686-93.
Yoon HJ, Ahn Y, Park JB, Park CG, Youn HJ, Choi DJ et al. Are metabolic risk factors and target organ damage more frequent in masked hypertension than in white coat hypertension? Clin Exp Hypertens 2010;32:480-5.